GH Pulse Stack: Ipamorelin + CJC-1295 Research Protocol & Evidence

Introduction

Growth hormone (GH) secretagogue research has identified synergistic peptide combinations that amplify endogenous GH pulse amplitude and duration beyond single-agent protocols. The GH Pulse Stack—combining Ipamorelin and CJC-1295 (no DAC)—represents one of the most studied two-peptide combinations in research literature.

This protocol leverages two distinct GH-stimulating mechanisms: Ipamorelin acts as a selective ghrelin receptor agonist, while CJC-1295 (no DAC) functions as a growth hormone-releasing hormone (GHRH) analog. Together, they create a synergistic effect that research suggests may amplify GH secretion 2–10× beyond either peptide alone.

Mechanism of Action

Ipamorelin: Selective Ghrelin Receptor Agonism

Ipamorelin is a pentapeptide (Aib-His-D-2-methylTrp-Ala-Trp-NH2) that selectively binds to ghrelin receptors (GHS-R1a) in the hypothalamus and anterior pituitary. Unlike GHRP-2 and GHRP-6, Ipamorelin exhibits minimal stimulation of cortisol and prolactin—a critical advantage for long-term research protocols.

Key mechanism:

• Selective GHS-R1a agonism → stimulates pituitary somatotrophs
• Ghrelin-independent mechanism → minimal hunger/appetite side effects (compared to GHRP analogs)
• Half-life ~2 hours (SC administration)
• Receptor desensitization risk after 4–8 weeks of continuous dosing → necessitates cycling

CJC-1295 (no DAC): GHRH Analog

CJC-1295 without DAC (drug affinity complex) is a 30-amino-acid synthetic GHRH analog. Unlike the DAC-modified version (which has a 7-day half-life), the “no DAC” form has a ~2–4 hour half-life, making it suitable for pulsatile GH secretion protocols.

Key mechanism:

• GHRH receptor agonism → stimulates GHRH receptors on pituitary somatotrophs
• Amplifies GH pulse amplitude and duration when paired with a ghrelin agonist
• Enhances endogenous GHRH signaling
• Half-life ~2–4 hours (SC)

Synergistic Effect: GHRH + Ghrelin Agonist

The amplification occurs at the pituitary level:

1. Ipamorelin (ghrelin analog) increases GH pulse frequency and amplitude
2. CJC-1295 (GHRH) potentiates somatotroph responsiveness to ghrelin signaling
3. Result: GH secretion that exceeds the sum of individual effects—research shows 2–10× amplification in animal models

Key Research Data

Study	Year	Design	Key Finding
Raun et al.	1998	Rat pituitary cell culture	Ipamorelin dose-dependently increased GH release; selectivity for GHS-R1a confirmed (Eur J Endocrinol, PMID: 9744532)
Broglio et al.	2002	Human open-label, single-dose	GHRP-6 + GHRH combination increased GH 5–8× vs. GHRH alone; establishes synergy model (J Clin Endocrinol Metab)
Walker RF et al.	2006	Review: GH insufficiency management	Sermorelin (GHRH) + GHRP combination superior to monotherapy in aging; supports combination approach
Arvat E et al.	1997	Healthy humans, acute dosing	GHRP-2 + GHRH: GH peak 10× higher than GHRH alone; demonstrates pituitary amplification

Comparative Potency

Research in animal models shows:

• Ipamorelin alone: 2–3× GH amplification vs. baseline
• CJC-1295 (no DAC) alone: 2–4× GH amplification vs. baseline
• Ipamorelin + CJC-1295 combination: 4–10× GH amplification vs. baseline (additive/synergistic effect)

Protocol Details

Dosing & Administration

Ipamorelin:

• Dose: 300 mcg per injection
• Frequency: 2–3× daily (morning, mid-day, evening)
• Route: Subcutaneous
• Timing: Fasted cardio, pre-sleep, or 2–3 hours post-meal

CJC-1295 (no DAC):

• Dose: 200 mcg per injection (paired with Ipamorelin)
• Frequency: 2–3× daily (same timing as Ipamorelin)
• Route: Subcutaneous
• Optimal timing: Pre-sleep injection often preferred due to natural nocturnal GH surge

Cycling Recommendation

Due to receptor desensitization risk (particularly at GHS-R1a):

• On-cycle: 4–6 weeks of daily dosing
• Off-cycle: 1–2 weeks minimum (permits receptor sensitivity recovery)
• Duration: 12–16 weeks per full cycle (3–4 on-cycles)

Reconstitution (Typical Protocol)

For 5 mg Ipamorelin vial:

• Reconstitute with 5 mL sterile bacteriostatic water (0.9% NaCl or 0.9% benzyl alcohol)
• Concentration: 1 mg/mL
• Per 300 mcg dose: 30 units on a U-100 insulin syringe

For 2 mg CJC-1295 (no DAC) vial:

• Reconstitute with 2 mL bacteriostatic water
• Concentration: 1 mg/mL
• Per 200 mcg dose: 20 units on a U-100 insulin syringe

Synergies & Stacking Considerations

Why Pair Ipamorelin + CJC-1295?

1. Complementary mechanisms: Ghrelin agonism + GHRH agonism activate distinct but overlapping GH secretion pathways
2. Minimal side-effect overlap: Ipamorelin avoids cortisol/prolactin elevation (unlike GHRP-2/6); CJC-1295 has minimal direct cortisol effect
3. Physiological GH pulsing: Mimics endogenous GH pulsatile secretion (which occurs during sleep, fasting, and exercise)
4. Research precedent: Combination GHRH + GHRP protocols are established in clinical literature (though primarily with GHRP-6 or GHRP-2)

Compatible Additions

• IGF-1 Support: Some researchers add insulin-like growth factor-1 (IGF-1) analogs; however, this requires caution due to hyperglycemia risk
• Sleep Optimization: Maximizes endogenous GH secretion; stack works synergistically with sleep/exercise protocols
• Thyroid Support: Ensures optimal metabolic environment for GH action

Avoid Combination With

• GHRP-2/GHRP-6: Redundant ghrelin agonism; increases cortisol/prolactin risk without additional GH benefit
• Somatostatin analogs (octreotide, pasireotide): Directly antagonize GH secretion
• High-dose glucocorticoids: Suppress GH secretion

Safety & Side Effects

Common Observations

Ipamorelin + CJC-1295 combination:

1. Increased appetite (mild–moderate): Ghrelin agonism stimulates hypothalamic feeding centers. Generally less pronounced than with GHRP-2 but notable.

2. Flushing & vasodilation: Brief transient flushing (minutes) at injection site; usually resolves quickly.

3. Water retention: Elevated GH increases sodium retention and intracellular water accumulation. Mild—typically 2–4 lbs within first 2 weeks.

4. Carpel tunnel symptoms: Rare but possible with sustained GH elevation; wrist discomfort reported in <5% of research participants.

5. Hyperglycemia risk: Minimal with this combination (unlike GHRP-2). GH is counterregulatory to insulin; monitor fasting glucose if diabetic.

Receptor Desensitization

• GHS-R1a downregulation: Chronic stimulation (>6 weeks continuous) reduces receptor sensitivity
• Mitigation: Cycling (4 weeks on, 1 week off) permits receptor recovery
• Monitoring: If GH response blunts, extend off-cycle duration

Contraindications & Precautions

• Active malignancy: GH stimulates cell growth; contraindicated in cancer or recent cancer history
• Uncontrolled diabetes: Requires glucose monitoring (GH is diabetogenic)
• Severe hypertension: GH can elevate BP; monitor regularly
• Pregnancy/Breastfeeding: Insufficient safety data; not recommended

Drug Interactions

• Somatostatin analogs (octreotide): Direct antagonism; avoid concurrent use
• Estrogen therapy: May reduce GH secretion; requires higher dosing or adjustment
• Thyroid hormones: Enhance GH efficacy; ensure euthyroid state

Research Gaps & Limitations

No Human Clinical Trials

Critical note: No published randomized controlled trials of Ipamorelin + CJC-1295 combination exist in human subjects. All dosing and synergistic claims derive from:

• Animal model studies (primarily rat/mouse pituitary cultures)
• Extrapolation from single-peptide human data
• Observational reports and practitioner protocols

Unknowns

1. Optimal dose ratio: Does 1:1 molar ratio (300 mcg Ipamorelin : 200 mcg CJC-1295) maximize synergy? Untested in humans.
2. Long-term safety: No data beyond 12–16 weeks of continuous cycling
3. IGF-1 response: GH elevation doesn’t guarantee proportional IGF-1 increase; individual variation is high
4. Age/sex differences: Older adults and females may have different dose requirements; not systematically studied

Research Disclaimer

All information in this article is provided for research and educational purposes only. Ipamorelin and CJC-1295 are not approved by regulatory agencies (FDA, EMA) for human use in most jurisdictions. This content does not constitute medical advice.

Researchers considering peptide protocols must:

• Consult qualified healthcare providers
• Verify local regulations (many jurisdictions restrict sales/use)
• Obtain products from credible, tested sources
• Monitor health markers (IGF-1, glucose, lipids, BP) regularly
• Understand that individual responses vary widely

The protocols and data presented represent current research consensus; they are not predictive of personal outcomes.